| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36e958459e9b49d2e1242c225c2187fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f62544890553a471320732ca9d2f4c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_185b7e7f1aa3197fc1752177aec8aa70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 |
| filingDate |
2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a59f963a64ef831bce2c86978d238a75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a1abd592e355e74e2e55025e081b274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba5c32ece56fdec4278f779022d44316 |
| publicationDate |
2007-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007126825-A2 |
| titleOfInvention |
Combined mucosal and parenteral immunization against hiv |
| abstract |
HIV antigens are mucosally administered in one or more priming immunization(s), and then HIV antigens are parenterally administered in one or more boosting immunization(s). Thus the invention provides a method for raising an immune response in a patient, comprising: (i) administering a HIV antigen to the patient via a mucosal route; and then (ii) administering a HIV antigen to the patient via a parenteral route. The antigens will typically be adjuvanted. Preferred mucosal immunizations are via the intranasal route using a detoxified mutant of E.coli heat labile toxin as the adjuvant. Preferred parenteral immunizations are via the intramuscular route using an oil-in-water emulsion adjuvant. |
| priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |